Pay in 4 interest-free payments of $5.19 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
Recently, two randomized controlled trials (RCTs) demonstrated that tirzepatide, a dual GLP-1/GIP receptor agonists, reduced the AHI and hypoxic burden, and improved sleep-related patient-reported outcomes among individuals with moderate-to-severe OSA [24]
Document your current dose, how long you have been at that dose, your total weight loss to date, and any ongoing side effects
Maintaining muscle mass and coordination helps support the pelvic floor, improve overall stability, and reduce the risk of strain during GLP-1 therapy
doi: 10.1016/S2213-8587(21)00246-1 21 EdqvistJRawshaniAAdielsMBjorckLLindMSvenssonAMet al
Through distinct yet complementary receptor engagementsstimulation of the GHRH receptor and agonism of the GHSRit is believed to afford a nuanced approach to modulating GH pulsatility, amplitude, and duration
